BLFS

NEUTRALM&A

BioLife Solutions, Inc.

2026-09-15

Price

$36.39

+2.71%

This is the 2026-09-15 snapshot — the signals and analysis for BLFS as of this single trading day.

View full BLFS research hub →

Score3.2Watchlist

Signals3/8 DNA1/13 Act · 0/4 Risk

SentimentNEUTRALScore: 8

Volume0.9xvs 20d avg

Analysis

BioLife Solutions (BLFS) is currently trading as a definitive M&A arbitrage play following the July 2026 acquisition agreement with Repligen. The expiration of the HSR antitrust waiting period on September 3rd removed a major regulatory hurdle, cementing institutional confidence and driving the stock's PERFECT_STACK and SMA_BOUNCE technical signals. In a RISK_ON macro regime where corporate credit spreads are exceptionally tight at just 0.80%, systemic deal-break and financing risks are virtually non-existent, providing high conviction for this price discovery ahead of the October shareholder vote.

Fired Signals

GOLDEN CROSSMARKET LEADERPERFECT STACKSMA BOUNCE

Key Takeaways

Actionable Thesis: BLFS is a high-conviction M&A arbitrage play, heavily supported by recent regulatory clearance and institutional accumulation.
Key Risk: Because the merger consideration includes 0.1442 Repligen shares per BLFS share, any severe downside in Repligen's stock directly impacts BLFS's implied deal value.
What to Watch: Monitor the upcoming October 5th special shareholder vote and the $34.92 line-in-the-sand support level for any signs of deal friction.

← Back to 2026-09-15 View Full BLFS History →Yahoo Finance &nearr;